« Home

Home » Biosciences » Molecular Biology » Pecorino: Molecular Biology of Cancer 2e » Student resources » Hyperlinked bibliography » Chapter 09

Pecorino: Molecular Biology of Cancer 2e

Chapter 09

Further reading

Bergers, G. and Benjamin, L.E. (2003) Tumorigenesis and the angiogenic switch. Nature Rev. Cancer 3: 401-410. [DOI: 10.1038/nrc1093]

Carmeliet, P. and Jain, R.K. (2000) Angiogenesis in cancer and other diseases. Nature 407: 249-257. [PubMed: 11001068] [DOI: 10.1038/35025220]

Chang, C. and Werb, Z. (2001) The many faces of metalloproteases: cell growth, invasion, angiogenesis and metastasis. Trends Cell Biol. 11: S37-S43. [PubMed: 11684441] [DOI: 10.1016/S0962-8924(01)82222-4]

Coussens, L.M., Fingleton, B., and Matrisian, L.M. (2002) Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science 295: 2387-2392. [PubMed: 11923519] [DOI: 10.1126/science.1067100]

Cross, M.J., Dixelius, J., Matsumoto, T., and Claesson-Welsh, L. (2003) VEGF-receptor signal transduction. Trends Biochem. Sci. 28: 488-494. [PubMed: 13678960] [DOI: 10.1016/S0968-0004(03)00193-2]

Folkman, J. (2006) Antiangiogenesis in cancer therapy-endostatin and its mechanism of action. Exp. Cell Res. 312: 594-607. [PubMed: 16376330] [DOI: 10.1016/j.yexcr.2005.11.015]

George, D.J. and Moore, C. (2006) Angiogenesis inhibitors in clinical oncology. Update Cancer Ther. 1: 429-434. [DOI: 10.1016/j.uct.2006.08.006]

Hood, J.D. and Cheresh, D.A. (2002) Role of integrins in cell invasion and migration. Nature Rev. Cancer 2: 91-100. [DOI: 10.1038/nrc727]

Kaplan, R.N., Rafii, S., and Lyden, D. (2006) Preparing the 'Soil': the premetastatic niche. Cancer Res. 66: 11089-11093. [PubMed: 17145848] [DOI: 10.1158/0008-5472.CAN-06-2407]

Kerbel, R. and Folkman, J. (2002) Clinical translation of angiogenesis inhibitors. Nature Rev. Cancer 2: 727-739. [DOI: 10.1038/nrc905]

Madhusudan, S. and Harris, A.L. (2002) Drug inhibition of angiogenesis. Curr. Opin. Pharmacol 2: 403-414. [PubMed: 12127873] [DOI: 10.1016/S1471-4892(02)00184-4]

Malik, A.K. and Gerber, H.-P. (2004) Targeting VEGF ligands and receptors in cancer. Targets 2: 48-57. [DOI: 10.1016/S1477-3627(03)02292-X]

McCarty, M.F., Liu, W., Fan, F., Parikh, A., Reimuth, N., Stoeltzing, O., and Ellis, L.M. (2003) Promises and pitfalls of anti-angiogenic therapy in clinical trials. Trends Mol. Med. 9: 53-58. [PubMed: 12615038] [DOI: 10.1016/S1471-4914(03)00002-9]

Matter, A. (2001) Tumour angiogenesis as a therapeutic target. Drug Discov. Today 6: 1005-1020. [PubMed: 11576867] [DOI: 10.1016/S1359-6446(01)01939-0]

Oppenheimer, S.B. (2006) Cellular basis of cancer metastasis: a review of fundamentals and new advances. Acta Histochem. 108: 327-334. [PubMed: 16730054] [DOI: 10.1016/j.acthis.2006.03.008]

Ruegg, C., Hasmim, M., Lejeune, F., and Alghisi, G.C. (2006) Antiangiogenic peptides and proteins: from experimental tools to clinical drugs. Biochim. Biophys. Acta 1765: 155-177. [PubMed: 16263219]

Ruoslahti, E. (2002) Specialization of tumour vasculature. Nature Rev. Cancer 2: 83-90. [DOI: 10.1038/nrc724]

Steeg, P.S. (2003) Metastasis suppressors alter the signal transduction of cancer cells. Nature Rev. Cancer. 3: 55-63. [DOI: 10.1038/nrc967]

Taraboletti, G. and Margosio, B. (2001) Antiangiogenic and antivascular therapy for cancer. Curr. Opin. Pharmacol 1: 378-384. [PubMed: 11710736] [DOI: 10.1016/S1471-4892(01)00065-0]

Yang, J., Mani, S.A., and Weinberg, R.A. (2006) Exploring a new twist on tumor metastasis. Cancer Res. 66: 4549-4552. [PubMed: 16651402] [DOI: 10.1158/0008-5472.CAN-05-3850]

Selected Special Topics

Blakey, D.C., Ashton, S.E., Westwood, F.R., Walker, M., and Ryan, A.J. (2002) ZD6126: A novel small molecule vascular targeting agent. Int. J. Radiat. Oncol. Biol. Phys. 54: 1497-1502. [PubMed: 12459377]

Griggs, J., Metcalfe, J.C., and Hesketh, R. (2001) Targeting tumor vasculature: the development of combretastatin A. Lancet Oncol. 2: 82-87. [PubMed: 11905799] [DOI: 10.1016/S1470-2045(00)00224-2]

Gupta, G.P., Nguyen, D.X., Chiang, A.C., Bos, P.D., Kim, J.Y., Nadal, C., Gomis, R.R., Monova-Todorova, K., and Massague, J. (2007) Mediators of vascular remodeling co-opted for sequential steps in lung metastasis. Nature 446: 765-770. [DOI: 10.1038/nature05760]

Gutheil, J.C., Campbell, T.N., Pierce, P.R., Watkins, J.D., Huse, W.D., Bodkin, D.J., and Cheresh, D.A. (2000) Targeted antiangiogenic therapy for cancer using Vitaxin: a humanized monoclonal antibody to the integrin αvβ3. Clin. Cancer. Res. 6: 3056-3061. [PubMed: 10955784]

Hood, J.D., Bednarski, M., Frausto, R., Guccione, S., Reisfeld, R.A., Xiang, R., and Cheresh, D.A. (2002) Tumor regression by targeted gene delivery to the neovasculature. Science 296: 2404-2407. [PubMed: 12089446] [DOI: 10.1126/science.1070200]

Kim, W. and Kaelin, W.G., Jr (2003) The von-Hippel-Lindau tumor repressor protein: new insights into oxygen sensing and cancer. Curr. Opin. Genet. Dev. 13: 55-60. [PubMed: 12573436] [DOI: 10.1016/S0959-437X(02)00010-2]

Laferriere, J. Houle, F., and Huot, J. (2002) Regulation of the metastatic process by E-selectin and stress-activated protein kinase-2/p38. Ann. NY Acad. Sci. 973: 562-572. [PubMed: 12485930]

Tucker, G.C. (2002) Inhibitors of integrins. Curr. Opin. Pharmacol. 2: 394-402. [PubMed: 12127872] [DOI: 10.1016/S1471-4892(02)00175-3]

Yang, J.C., Haworth, L., Sherry, R.M., Hwu, P., Schwartzentruber, D.J., Topalian, S.L., Steinberg, S.M., Chen, H.X., and Rosenberg, S.A. (2003) A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody for metastatic renal cancer. N Engl J. Med. 349: 427-434. [DOI: 10.1056/NEJMoa021491]